The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Share News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 64.50
Bid: 63.00
Ask: 66.00
Change: 1.00 (1.57%)
Spread: 3.00 (4.762%)
Open: 63.00
High: 66.50
Low: 61.50
Prev. Close: 64.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS UPDATES: Live Co achieves surge in interim revenue

Fri, 30th Sep 2022 14:46

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

DG Innovate PLC - Bingley-England based storage battery manufacturer - Says grant income in the six months ended on June 30 falls to GBP344,831, from GBP675,816 a year ago. Pretax loss widens to GBP6.2 million from just GBP201,156, as administrative expenses jump to GBP1.2 million from GBP777,670 a year ago. "The first half of 2022 was transformational for the company, as we completed the reverse takeover of DGI to become DG Innovate PLC", Chair Nick Tulloch says. Looking ahead, it seeks to commercialise a suite of electric mobility and storage tech.

----------

Live Co Group PLC - UK-based live events and entertainment company - Posts a surge in revenue to GBP2.6 million for the six months ended on June 30, from GBP622,000 a year ago, as pretax loss narrows to GBP1.4 million from GBP2.1 million. Cost of sales increase to GBP1.7 million from GBP1.4 million a year earlier. Looking ahead, says it remains "cautiously optimistic" for 2023, citing increased demand for live events.

----------

NetScientific PLC - London-based life sciences and sustainability technology investment firm - Reports a fall in revenue to GBP391,000 for the six months ended June 30, from GBP407,000 a year ago. Pretax loss widens to GBP1.7 million from GBP1.5 million. Selling and administrative costs amount to GBP1.4 million, up from GBP1.2 million ago, mainly due to "increased headcount in the subsidiaries and at head office, and increased spending in drives towards commercialisation and eventual liquidity events".

----------

TechFinancials Inc - invests in early-stage technology companies - Posts no revenue for the six months ended on June 30. Pretax loss widens to USD163,000 from USD92,000 a year ago as financing expenses swing to a loss of USD89,000 from a profit of USD41,000.

----------

Apollon Formularies PLC - London-based medical cannabis pharmaceutical firm - Posts revenue of GBP165,053 in the six months ended on June 30, compared to none a year ago. Pretax loss narrows to GBP212,436 from GBP1.7 million, despite administrative expenses rising to GBP535,889 from GBP335,425 a year ago. No finance costs have incurred this year, compared to GBP3,799 last year.

-----------

By Xindi Wei; xindiwei@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
13 May 2024 18:55

EARNINGS AND TRADING: itim loss narrows; Vela trims EnSilica stake

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
10 May 2024 13:19

IN BRIEF: NetScientific says PDS Biotech's Versamune meets endpoints

NetScientific PLC - London-based deep tech and life sciences venture capital investor - Says its portfolio company, PDS Biotechnology Corp's Versamune meets endpoints in a phase three trial for patients with HPV. NetScientific holds a 3.5% shareholding in PDS. Versamune is a T cell-activating platform that effectively stimulates a precise immune system response to a cancer-specific protein.

Read more
15 Apr 2024 11:06

NetScientific investee secures funding to develop product range

(Alliance News) - NetScientific PLC on Monday said its portfolio company ProAxsis Ltd secured GBP1.8 million in investment.

Read more
27 Mar 2024 18:47

TRADING UPDATES: Empire Metals targets key milestones in Australia

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
13 Mar 2024 17:04

NetScientific "significantly" advances strategic goals

(Alliance News) - NetScientific PLC on Wednesday released a portfolio and strategy update.

Read more
23 Jan 2024 18:39

TRADING UPDATES: Esken's Southend Airport faces further allegations

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
1 Dec 2023 11:59

IN BRIEF: NetScientific investee DeepTech Recycling bags GBP1 million

NetScientific PLC - technology and life sciences investor - Portfolio company DeepTech Recycling Ltd closes GBP1 million fundraising. DeepTech, in which NetScientific holds a 30% stake, is a company focused on chemical recycling of plastic waste. Last December, it bought the assets of Recycling Technologies Ltd out of administration. The fundraise is carried out via an advance share subscription agreement and is the first closing of a target investment programme of around GBP3 million, with further investment anticipated within the next six months.

Read more
9 Nov 2023 19:41

IN BRIEF: NetScientific's portfolio company updates on cancer trial

NetScientific PLC - London-based deep tech and life sciences-focused venture capital investor -

Read more
6 Nov 2023 12:00

IN BRIEF: NetScientific says Ventive on fire with new investment

NetScientific PLC - London-based deep tech and life sciences-focused venture capital investor - Says portfolio company Ventive, a London-based designer and manufacturer of heating and ventillation solutions, has successfuly closed a new investment of around GBP900,000. Funding included GBP316,000 from existing shareholders and the conversion of two existing convertible loans valued at about GBP600,000. Investment is part of Ventive's proposed GBP1 million to GBP1.5 million programme, with further investments expected by April 30. NetScientific now holds an 11% total equity stake in Ventive, with a post-investment fair value of GBP893,000 - up from GBP52,000 at December 31.

Read more
23 Oct 2023 21:10

NetScientific investee claims promising results in biomarker study

(Alliance News) - NetScientific PLC on Monday said its investee PDS Biotechnology Corp was "encouraged" by study data for its PDS0101 combined with Merck & Co Inc's drug Keytruda.

Read more
3 Oct 2023 17:12

IN BRIEF: NetScientific portfolio company updates on cancer trial

NetScientific PLC - London-based deep tech and life sciences-focused venture capital investment company - Reports that its portfolio company, PDS Biotechnology Corp, has announced updated interim data from the Versatile-002 phase two clinical trial evaluating PDS0101 in combination with Merck & Co Inc's Keytruda in patients with unresectable, recurrent, or metastatic HPV16-positive head and neck squamous cell carcinoma.

Read more
28 Sep 2023 14:24

EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
13 Sep 2023 21:32

NetScientific's Q-Bot completes GBP3.5 million investment programme

(Alliance News) - NetScientific PLC on Wednesday said that its portfolio company, Q-Bot, has successfully closed a GBP3.5 million investment programme.

Read more
14 Aug 2023 19:49

IN BRIEF: NetScientific's PDS suffers wider loss as R&D costs mount

NetScientific PLC - London-based investment firm focused on life science, sustainability and technology companies - Portfolio company PDS Biotechnology Corp reports results for the quarter to June 30. Net loss was USD11.5 million, widened from USD5.8 million the year before. Higher loss primarily due to costs incurred in connection with research and development programmes, which more than doubled to USD8.0 million from USD3.8 million. Loss per share of USD0.37 compared to USD0.20 before. Further, PDS reports the successful submission of final clinical protocol and supporting information to the US Food & Drug Administration to initiate phase 3 Versatile-003 trial in the fourth quarter. Adds biomarker data from Versatile-002 will be presented at the European Society for Medical Oncology Congress.

Read more
30 Jun 2023 14:07

TRADING UPDATES: Pendragon quarterly trading momentum maintained

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.